Please enjoy this video covering the history of biologic medicines, differences between innovator biologics and biosimilars, and current policy considerations –courtesy of ASBM member group the Gastrointestinal Society.
On July 13th, the Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) met to consider approval of two biosimilar applications. In the morning session, the ODAC considered Amgen’s biosimilar application for Genentech/Roche’s Avastin (bevacizumab); in the afternoon session, the ODAC considered Mylan GmbH’s application for Genentech’s Herceptin (trastuzumab). ASBM Chairman Harry L. Gewanter, MD testified at both sessions. […]
On June 28th, ASBM Chairman Harry L. Gewanter, MD presented to an audience of 150 at the 8th Latin American Biosimilars Forum in Brasilia, Brazil. In his presentation, entitled “Increasing Physician Confidence in Biosimilars”, Dr. Gewanter discussed barriers to widespread acceptance of biosimilars among physicians. Dr. Gewanter cited the example of Australia, where biosimilar uptake remains […]